Literature DB >> 21850696

Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment.

Hans J Schlitt1, Andreas A Schnitzbauer.   

Abstract

KEY POINTS: 1. Adjuvant/neoadjuvant chemotherapy. 2. Neoadjuvant transarterial chemoembolization. 3. Kinase inhibitors (eg, sorafenib). 4. Antiviral treatment. 5.Immunosuppressive treatment after liver transplantation. 6. Disseminated tumor cells: the basis for innovative treatment options?
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21850696     DOI： 10.1002/lt.22411

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


  7 in total

1.  Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Authors:  Atsushi Kudo; Kaoru Mogushi; Tadatoshi Takayama; Satoshi Matsumura; Daisuke Ban; Takumi Irie; Takanori Ochiai; Noriaki Nakamura; Hiroshi Tanaka; Naohiko Anzai; Michiie Sakamoto; Shinji Tanaka; Shigeki Arii
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

Review 2.  [Operative therapy of hepatocellular carcinoma].

Authors:  S A Farkas; H J Schlitt
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 3.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

4.  Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

Authors:  Yafei Zhang; Bicheng Zhang; Anran Zhang; Yong Zhao; Jie Zhao; Jian Liu; Jianfei Gao; Dianchun Fang; Zhiguo Rao
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

5.  Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma.

Authors:  Kirti Shetty; Chiranjeev Dash; Jacqueline Laurin
Journal:  J Transplant       Date:  2014-04-10

6.  Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.

Authors:  Arno Kornberg; Ulrike Witt; Edouard Matevossian; Bernadett Küpper; Volker Assfalg; Alexander Drzezga; Norbert Hüser; Moritz Wildgruber; Helmut Friess
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

7.  Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection.

Authors:  Shun-Li Shen; Shun-Jun Fu; Xiong-Qing Huang; Bin Chen; Ming Kuang; Shao-Qiang Li; Yun-Peng Hua; Li-Jian Liang; Bao-Gang Peng
Journal:  BMC Cancer       Date:  2014-10-03       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.